Please login to the form below

Not currently logged in
Email:
Password:

Impact Biomedicines

This page shows the latest Impact Biomedicines news and features for those working in and with pharma, biotech and healthcare.

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

The approval of Inrebic – a selective JAK2 inhibitor – means that Celgene can start to get a return on its $1.1bn upfront acquisition of Impact Biomedicines, which gave it rights to ... Impact was originally formed in 2016 after the acquisition of

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Acquisition company -  remaining 90%. 9, 000. Impact Biomedicines/ Celgene.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics